Geovax announces presentation of preliminary data from clinical trial of next-generation covid-19 vaccine candidate

Atlanta, ga, april 06, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, presented an update on the development of its sars-cov-2 vaccine, geo-cm04s1, including preliminary data from an ongoing phase 2 clinical trial, during the 23rd annual world vaccine congress taking place in washington, dc.
GOVX Ratings Summary
GOVX Quant Ranking